Revenue GrowthThe significant revenue growth in 2024 indicates a positive shift in market demand and operational efficiency, suggesting potential for sustained business expansion.

Margin SustainabilityHigh margins reflect strong pricing power and cost control, which can support long-term profitability and competitive positioning.

Balance Sheet HealthA debt-free balance sheet reduces financial risk and enhances flexibility for future investments or downturns, supporting long-term stability.

Bears Say

Earnings Quality RiskLow cash flow coverage of net income raises concerns about the quality of earnings, potentially impacting future financial stability and investor confidence.

Volatile Financial HistoryPast financial instability suggests potential challenges in maintaining recent improvements, posing risks to long-term performance consistency.

Cash Conversion ConcernsWeak cash conversion indicates potential issues with working capital management or revenue recognition, which could affect future liquidity and operational efficiency.

S21 FAQ

What was S2Medical AB Class B’s price range in the past 12 months?

Currently, no data Available

What is S2Medical AB Class B’s market cap?

S2Medical AB Class B’s market cap is €874.33K.

When is S2Medical AB Class B’s upcoming earnings report date?

S2Medical AB Class B’s upcoming earnings report date is Feb 20, 2026 which is in 4 days.

How were S2Medical AB Class B’s earnings last quarter?

S2Medical AB Class B released its earnings results on Dec 01, 2025. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.

Is S2Medical AB Class B overvalued?

According to Wall Street analysts S2Medical AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does S2Medical AB Class B pay dividends?

S2Medical AB Class B does not currently pay dividends.

What is S2Medical AB Class B’s EPS estimate?

S2Medical AB Class B’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does S2Medical AB Class B have?

S2Medical AB Class B has 898,657,040 shares outstanding.

What happened to S2Medical AB Class B’s price movement after its last earnings report?

S2Medical AB Class B reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 100%.

Which hedge fund is a major shareholder of S2Medical AB Class B?

Currently, no hedge funds are holding shares in DE:S21

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

S2Medical AB Class B

S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds. It offers INSTAQRETT, a sterile single use mechanical debridement tool; EPIPROTECT SafeStop for blood stilling; Instagraft, a single-use medical device for the treatment of chronic and complicated wounds; EPIPROTECT tissue substitutes; and washable, waterproof, and self-adhesive bandages under the INSTABIND brand name. The company also distributes Silverlon dressings that deliver silver ions into the wound. In addition, it operates wound healing center under the S2Clinic name. The company was founded in 2013 and is headquartered in Linköping, Sweden.